medlogicai.org

Clinical intelligence. Better decisions.

Decision-Making Algorithm in Otorhinolaryngology & Head and Neck Surgery

Neoplasms of the Tongue

The tongue lesion from tip to base — benign, premalignant, oral-tongue SCC and the HPV-driven base of tongue, with the glossectomy and reconstruction ladder

Step 1

Step 1 of 14

Presentation & Tongue Subsite

Non-healing ulcer/mass · pain/otalgia · dysarthria · the oral-tongue vs base-of-tongue split

A tongue neoplasm presents as an ulcer, mass, or swelling, often with pain, referred otalgia, bleeding, a foreign-body sensation, dysarthria, dysphagia, odynophagia, or, when advanced, restricted tongue mobility, loose teeth, weight loss, and a neck swelling. The first and most consequential observation is the subsite, because the tongue behaves as two different organs: the oral (mobile) tongue — tip, lateral border, ventral surface, and dorsum (anterior two-thirds) — and the base of tongue (posterior third), which lies in the oropharynx.

The lateral border of the oral tongue is the classic site of squamous cell carcinoma. The base of tongue is clinically silent for longer — it often presents late with a cystic neck node, muffled "hot-potato" voice, odynophagia, or referred otalgia rather than a visible ulcer — and is biologically and therapeutically distinct because it is frequently HPV-driven. Defining the subsite at the outset routes the whole pathway: the oral tongue toward a surgically-led plan, the base of tongue toward the oropharyngeal, HPV-stratified one.

  • Symptoms — non-healing ulcer/mass, pain, referred otalgia, dysarthria, dysphagia, bleeding, neck node, weight loss
  • Oral (mobile) tongue — tip, lateral border, ventral, dorsum (anterior two-thirds); lateral border is the classic SCC site
  • Base of tongue (posterior third) — oropharyngeal, often HPV-driven; presents late with a cystic neck node or muffled voice
  • Subsite decides the pathway — oral tongue is surgically led, base of tongue is (chemo)RT/TORS-led

★ High-yield pearls (chapter-wide)

  • A tongue ulcer that has not healed in two to three weeks is cancer until biopsy proves otherwise — the lateral border of the oral tongue is the classic site, and induration is the most worrying single sign.
  • The tongue is two different organs oncologically — the oral tongue (anterior two-thirds) is a tobacco-and-alcohol surgical cancer, while the base of tongue (posterior third) is an HPV-driven oropharyngeal cancer treated very differently.
  • Depth of invasion, not surface size, predicts the occult node — a small but deep oral-tongue cancer earns an elective neck, and DOI now sits inside the AJCC 8th-edition T category.
  • Oral-tongue cancer is surgically led; base-of-tongue cancer is led by (chemo)radiotherapy or transoral robotic surgery — do not transfer one paradigm to the other.
  • Elective neck dissection beats watchful waiting for survival in early node-negative oral-tongue cancer — the D'Cruz trial settled it, and the oral tongue skips to level IV, so the dissection is extended there.
  • p16/HPV positivity is favourable in the base of tongue but does NOT rescue the prognosis of the oral tongue — same histology, opposite prognostic meaning by subsite.
  • Margins shrink on the specimen — take a generous gross margin (~1 cm) to land a clear (≥5 mm) histological margin, and confirm with intra-operative frozen section.
  • Reconstruction follows defect size — primary closure under ~30%, skin graft or local flap for 30–50%, and a free flap (radial forearm for soft tissue, fibula for composite mandible) above 50%.
  • Positive margins or extranodal extension on final pathology mandate concurrent cisplatin chemoradiotherapy, not radiotherapy alone (RTOG 9501 / EORTC 22931).
  • Most tongue swellings are benign — fibroma, papilloma, haemangioma, granuloma — and a smooth, mobile, painless, non-ulcerated lesion is observed or simply excised, not staged as cancer.

Evidence base

4 sources
  1. MOD

    Ettinger KS, Ganry L, Fernandes RP · Oral Maxillofac Surg Clin North Am · 2019Narrative reviewPMID 30454788

    Comprehensive review of oral cavity cancer — presentation, surgical management, the neck, reconstruction, and rehabilitation.

  2. MOD

    Dunn LA, Ho AL, Pfister DG · JAMA · 2026Narrative reviewPMID 41396597

    Contemporary JAMA review of head-and-neck cancer — staging, treatment paradigms by subsite, and systemic therapy.

  3. MOD

    Lechner M et al. · Nat Rev Clin Oncol · 2022Narrative reviewPMID 35105976

    Reviews HPV-driven oropharyngeal cancer — the biology and management that distinguish the base of tongue from the carcinogen-driven oral tongue.

  4. MOD

    Mummudi N et al. · Clin Oncol (R Coll Radiol) · 2019Narrative reviewPMID 31174947

    Reviews the epidemiology and burden of oral cancer in the Indian subcontinent, driven by tobacco and areca nut.

Decision tree

The triage screen is the first gate. Classification routes the stable patient to one of the aetiology-keyed pathways below. Cross-cut cards capture the chapter's must-not-miss rules.

Step 1 — TriageRed-flag screenNo red flagPathway classification?Benign (A)Most tongue swellings are benign, and the clinical picture isreassuring — smooth, mobile, well-circumscribed, painless,non-ulcerated lesions withou…Premalignant (B)Oral potentially-malignant disorders (OPMD) of the tongue aremanaged to prevent, or catch early, the cancer they precede.Leukoplakia (white patch) …Early oral (C)Early oral-tongue cancer (T1–T2, clinically N0) is treated byprimary surgery — transoral partial glossectomy with clearmargins combined with depth-…Advanced oral (D)Locally advanced but resectable oral-tongue cancer (T3–T4a, ornode-positive) is treated by glossectomy (hemi-, extended hemi-,subtotal, or total) w…Base of tongue (E)Base-of-tongue carcinoma is an oropharyngeal cancer and ismanaged on a different paradigm from the oral tongue. It isfrequently HPV-driven (p16-pos…Glossectomy (F)The resection and its reconstruction are planned together alongtwo matched ladders. The glossectomy ladder scales with tumourvolume — partial gloss…Neck (G)The neck is managed by nodal status, depth, and laterality. Theclinically negative (cN0) neck is decided by depth of invasion:DOI <4 mm may be obse…Adjuvant (H)Adjuvant therapy is matched to the pathology risk. Low-riskdisease — T1–T2, N0–N1, negative margins, no PNI/LVI — is treatedby surgery alone. Inter…Unresectable (I)Disease that is unresectable (T4b) — masticator-space extensionto the skull base, pterygoid-plate or skull-base involvement,internal-carotid encase…Recurrent/metastatic (J)Recurrence is restaged (CT/MRI, PET-CT, biopsy) and triaged bysite. Resectable local recurrence (or a new second primary in thefield) is treated by…Pathways:A BenignB PremalignantC Early oralD Advanced oralE Base of tongueF GlossectomyG NeckH AdjuvantI UnresectableJ Recurrent/metas…
Step 1

Disclaimer

For educational purposes only. Not for clinical use. This platform is an instructional resource intended to support learning about clinical decision-making and the interpretation of investigations. Clinicians remain completely responsible for the interpretation of findings, the formulation of a differential diagnosis, and any clinical decision. Nothing in this application replaces individualized assessment, hands-on training, expert consultation, or established practice guidelines.

Not for profit effort by

Dr. Prahlada N.B

  • MBBS (JJMMC), MS (PGIMER, Chandigarh)
  • MBA in Hospital & Healthcare Management (BITS, Pilani)
  • Postgraduate Certificate in Technology Leadership and Innovation (MIT, USA)
  • Executive Programme in Strategic Management (IIM, Lucknow)
  • Senior Management Programme in Healthcare Management (IIM, Kozhikode)
  • Advanced Certificate in AI for Digital Health and Imaging Program (IISc, Bengaluru)

Supporting organisations

  • Karnataka ENT Hospital and Research Centre (R)
  • Champions Educational and Medical Society (R)
  • Amogh Foundation